Bristol Myers Squibb (BMY) Other financing activities (2009 - 2022)

Bristol Myers Squibb (BMY) has reported Other financing activities for 14 consecutive years, with $179.0 million the latest figure, recorded in Q4 2022.

• On a quarterly basis, Other financing activities rose 6066.67% year-over-year to $179.0 million in Q4 2022; TTM through Dec 2022 was $984.0 million, a 53.51% increase from a year earlier, with the FY2023 full-year figure at $27.0 million, down 97.26% from the prior year.
• Other financing activities was $179.0 million for Q4 2022 at Bristol Myers Squibb, up from $53.0 million in the prior quarter.
• Over five years, Other financing activities peaked at $419.0 million in Q2 2022 and troughed at -$58.0 million in Q1 2018.
• A 5-year average of $103.0 million and a median of $35.5 million in 2020 frame the typical range for Other financing activities.
• Across the five-year window, Other financing activities sank 1400.0% in 2019 and soared 17200.0% in 2020, its largest moves.
• Over 5 years, Other financing activities stood at $1.0 million in 2018, then slumped by 1400.0% to -$13.0 million in 2019, then jumped by 2230.77% to $277.0 million in 2020, then tumbled by 101.08% to -$3.0 million in 2021, then surged by 6066.67% to $179.0 million in 2022.
• The last three Other financing activities figures came in at $179.0 million (Q4 2022), $53.0 million (Q3 2022), and $419.0 million (Q2 2022), per Business Quant data.